Nouvelle déclaration d'incident
No de la demande: 2020-2296
Numéro de référence du titulaire d'homologation: 2019-CA-000179
Nom du titulaire (nom légal complet, aucune abbréviation): The Hartz Mountain Corporation
Adresse: 400 Plaza Drive
Ville: Secaucus
État: New Jersey
Pays: USA
Code postal /Zip: 07094-3688
Incident chez un animal domestique
Pays: CANADA
État: BRITISH COLUMBIA
ARLA No d'homologation 30734 ARLA No de la demande d'homologation EPA No d'homologation.
Nom du produit: Hartz UltraGuard Flea and Tick Drops for Dogs 14 - 28 kg
Oui
Inconnu
Site: Animal / Usage sur un animal domestique
Non
Propriétaire de l'animal
Dog / Chien
Bichon Frise
1
Homme
1
2
kg
Cutanée
>3 days <=1 wk / >3 jours <=1 sem
<=30 min / <=30 min
Système
Unknown / Inconnu
Non
Non
Unknown/Inconnu
Treatment / Traitement
(p.ex. description des symptômes tels que la fréquence et la gravité
On 16-Nov-2019, a 1 year old, approximately 2 kg, intact, male, Bichon Frise dog, in unknown condition, with no known concomitant medical condition, was administered approximately 0.5 tube of Hartz UltraGuard Flea and Tick Drops for Dogs 14 - 28 kg (Phenothrin) via the topical route by the animal owner's friend. The product was used extra label for the weight of the dog and only half the product was applied. Approximately one minute post application, the dog exhibited generalized pruritus, generalized chewing at the skin, and generalized erythema. The dog was not evaluated by a veterinarian, no treatments were performed and the clinical signs persisted at the time of the call. Bathing the dog with liquid dish soap twice, and applying a cool compress and vitamin E oil to the application site was recommended. Also recommended further veterinary evaluation if the signs persisted. No further information was received in this case.
Mineure
The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.